TRIcvalve BiCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)

P+F Products + Features USA Inc.

Status

Enrolling

Conditions

Tricuspid Valve Disease

Tricuspid Regurgitation

Treatments

Device: TricValve® Transcatheter Bicaval Valve System

Study type

Interventional

Funder types

Industry

Identifiers

NCT06137807

CTP-TRIC-005

Details and patient eligibility

About

The TricValve® Transcatheter Bicaval Valve System is a bicaval transcatheter tricuspid valve replacement system, which includes the TricValve® Transcatheter Bicaval Valve for superior vena cava (SVC) and the TricValve® Transcatheter Bicaval Valve for inferior vena cava (IVC). The TricValve® Transcatheter Bicaval Valves are pre-mounted into the TricValve® Delivery System which is used for percutaneous access and delivery of the TricValve® Transcatheter Bicaval Valve in the vena cava. The system is a single use, sterile device compatible with all the valve sizes. The prostheses are implanted percutaneously into the inferior and superior vena cava without disturbing the native tricuspid valve. The device is made of bovine pericardium leaflets sutured on a nitinol self-expanding stent system.

Full description

This is a prospective multicenter clinical investigation designed to evaluate the safety and effectiveness of the TricValve® Transcatheter Bicaval Valve System for improving outcomes in symptomatic subjects with severe TR deemed by the local Heart Team to be at high risk for tricuspid valve surgery.

Patients who meet all of the study inclusion criteria, will be treated with the TricValve System. After the intervention, patients will be followed up closely for 12 months. Long term safety and efficacy data will be collected annually up to 5 years.

Enrollment

15 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subject must be 18 years or older, at the time of signing the informed consent.
Subjects has severe tricuspid regurgitation (TR), as determined by the qualifying transthoracic echocardiogram (TTE) confirmed by an echocardiography Core Lab.
NYHA Class III-IVa (not on inotropes, IABP or LVAD) or heart failure (HF) admission in the past 6 months.
Subject is adequately treated with optimal medical therapy (OMT) for heart failure per the local Heart Team for at least 30 days prior to the index procedure, including a diuretic.
The local Heart Team and IEC determine that the patient is eligible for the TricValve procedure.
For females of childbearing potential, negative pregnancy test.
Capable of giving signed informed consent.

Exclusion criteria

Subject had a recent MI, stroke or cardiovascular accident; underwent coronary artery bypass graft surgery, had a percutaneous coronary intervention or other major cardiovascular surgery within 90 days prior to TricValve implantation.
Subject requires another planned major cardiac procedure, including left-sided transcatheter intervention or surgery (e.g. severe aortic stenosis, severe mitral regurgitation), coronary artery bypass or PCI or pulmonary valve correction.
LVEF ≤ 30% on echocardiography.
Evidence of intracardiac, inferior vena cava (IVC), or femoral venous mass, thrombus or vegetation.
Tricuspid stenosis. (Per TVARC, echo criteria: TVA at least 1.5 cm2 or TVAi at least 0.9 cm2/m2 [at least 0.75 if BMI >30 kg/m2], DVI <2.2, mean gradient <5mm Hg); reduction of total tricuspid regurgitation to optimal (≤ mild [1+]) or acceptable (≤ moderate [2+]).
Severe right ventricular dysfunction.
Cardiac amyloidosis
Pulmonary artery systolic pressure (PASP) >65 mmHg assessed with Echo Doppler and /or right heart catheterization.
Lower extremity venous thrombosis and/or the presence of an IVC filter at the time of or 6 months prior to TricValve procedure.
Hemodynamically significant pericardial effusion.
Patient with refractory heart failure requiring advanced intervention (i.e. left ventricular assist device, transplantation) (ACC/ AHA/ ESC/ EACTS Stage D heart failure)
Any known allergy or hypersensitivity to nitinol, bovine tissue or contrast media that cannot be adequately treated with pre-medication.
Unable to tolerate anticoagulation/antiplatelet therapy
Hemodynamic instability, cardiogenic shock, inotropic support, intra-aortic balloon pump or acute heart failure within 30 days prior to the TricValve procedure.
Any known life-threatening condition with an estimated life span of at least 12 months.
Platelet count < 75,000/mm3
Child-Pugh Severity Class C (10-15 points).
Severe renal insufficiency with estimated glomerular filtration rate (eGFR) ≤ 25 mL/min/1.73 m2 or requiring chronic renal replacement therapy at the time of enrollment.
Endocarditis or active/ongoing infection requiring antibiotics.
Unable to walk at least 60 meters in a 6minute walk test.
Known bleeding or clotting disorders or patient refuses blood transfusion.
Active gastrointestinal (GI) bleeding within 3 months of randomization.
Presence of significant congenital heart disease including but not limited to hemodynamically significant atrial septal defect, RV dysplasia, and arrhythmogenic RV.
Use or participation in other investigational device or drug study in which patient has not reached a primary endpoint to treat cardiovascular conditions related to the outcomes of the current study.
Any other condition that would preclude ability to meet study requirements in the opinion of the investigator.
Psychiatric/behavioral issues or other medical or social conditions that preclude valid consent and follow-up
Pregnant or breastfeeding subjects and those who plan pregnancy during the clinical investigation follow-up period.